Konkurrenz für BioNTech: CureVac startet IPO an der Nasdaq – Preis steht fest

Das Tübinger Biotech-Unternehmen CureVac startet heute an der Börse in New York, um Geld für die Entwicklung seines Corona-Impfstoffs einzusammeln. Vor Börsenstart an der Nasdaq wurden nun die Details …
(Orginal – Story lesen…)

This website stores some user agent data. These data are used to provide a more personalized experience and to track your whereabouts around our website in compliance with the European General Data Protection Regulation. If you decide to opt-out of any future tracking, a cookie will be set up in your browser to remember this choice for one year. I Agree, Deny
662